Summit Therapeutics Inc. Increase (Decrease) in Contract with Customer, Liability
Summit Therapeutics Inc. (SMMT) reported Increase (Decrease) in Contract with Customer, Liability of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-24.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2025-02-24
- Summit Therapeutics Inc. increase (decrease) in contract with customer, liability for the quarter ending 2023-12-31 was $0.00, a 100.00% decline year-over-year.
- Summit Therapeutics Inc. increase (decrease) in contract with customer, liability for the quarter ending 2023-09-30 was $0.00.
- Summit Therapeutics Inc. increase (decrease) in contract with customer, liability for the quarter ending 2023-06-30 was $0.00.
- Summit Therapeutics Inc. increase (decrease) in contract with customer, liability for the quarter ending 2023-03-31 was $0.00.
- Summit Therapeutics Inc. increase (decrease) in contract with customer, liability for fiscal 2024 was $0.00.
- Summit Therapeutics Inc. increase (decrease) in contract with customer, liability for fiscal 2023 was $0.00.
- Summit Therapeutics Inc. increase (decrease) in contract with customer, liability for fiscal 2022 was -$7.28M.
- Summit Therapeutics Inc. increase (decrease) in contract with customer, liability for fiscal 2021 was -$813.00K, a 115.13% decline from fiscal 2020.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 11 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-02-24 | ||||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-24 | $0.00 derived: sum of 2 quarters · filed 2025-02-24 | $0.00 derived: sum of 3 quarters · filed 2025-02-24 | $0.00 10-K · filed 2025-02-24 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $0.00 derived: sum of 2 quarters · filed 2023-11-07 | $0.00 10-Q · filed 2023-11-07 | $276.00K derived: sum of 4 quarters · filed 2025-02-24 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $0.00 10-Q · filed 2023-08-09 | $276.00K derived: sum of 3 quarters · filed 2025-02-24 | -$3.15M derived: sum of 4 quarters · filed 2025-02-24 | |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-11 | $276.00K derived: sum of 2 quarters · filed 2025-02-24 | -$3.15M derived: sum of 3 quarters · filed 2025-02-24 | -$4.62M derived: sum of 4 quarters · filed 2025-02-24 | |
| 2022-12-31 | $276.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-24 | -$3.15M derived: sum of 2 quarters · filed 2025-02-24 | -$4.62M derived: sum of 3 quarters · filed 2025-02-24 | -$7.28M 10-K · filed 2025-02-24 | |
| 2022-09-30 | -$3.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$4.90M derived: sum of 2 quarters · filed 2023-11-07 | -$7.55M 10-Q · filed 2023-11-07 | -$7.03M derived: sum of 4 quarters · filed 2023-11-07 | |
| 2022-06-30 | -$1.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$4.13M 10-Q · filed 2023-08-09 | -$3.61M derived: sum of 3 quarters · filed 2023-08-09 | -$3.39M derived: sum of 4 quarters · filed 2023-08-09 | |
| 2022-03-31 | -$2.66M 10-Q · filed 2023-05-11 | -$2.13M derived: sum of 2 quarters · filed 2023-05-11 | -$1.92M derived: sum of 3 quarters · filed 2023-05-11 | -$2.27M derived: sum of 4 quarters · filed 2023-05-11 | |
| 2021-12-31 | $523.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $741.00K derived: sum of 2 quarters · filed 2023-03-09 | $387.00K derived: sum of 3 quarters · filed 2023-03-09 | -$813.00K 10-K · filed 2023-03-09 | |
| 2021-09-30 | $218.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$136.00K derived: sum of 2 quarters · filed 2022-11-09 | -$1.34M 10-Q · filed 2022-11-09 | -$1.25M derived: sum of 4 quarters · filed 2022-12-21 | |
| 2021-06-30 | -$354.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$1.55M 10-Q · filed 2022-08-11 | -$1.47M derived: sum of 3 quarters · filed 2022-12-21 | $735.00K derived: sum of 4 quarters · filed 2022-12-21 | |
| 2021-03-31 | -$1.20M 10-Q · filed 2022-05-11 | -$1.11M derived: sum of 2 quarters · filed 2022-12-21 | $1.09M derived: sum of 3 quarters · filed 2022-12-21 | $2.44M derived: sum of 4 quarters · filed 2022-12-21 | |
| 2020-12-31 | $86.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-12-21 | $2.29M derived: sum of 2 quarters · filed 2022-12-21 | $3.65M derived: sum of 3 quarters · filed 2022-12-21 | $5.37M 10-K/A · filed 2022-12-21 | |
| 2020-09-30 | $2.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $3.56M derived: sum of 2 quarters · filed 2021-11-15 | $5.29M 10-Q · filed 2021-11-15 | ||
| 2020-06-30 | $1.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $3.08M 10-Q · filed 2021-08-12 | |||
| 2020-03-31 | $1.73M 10-Q · filed 2021-05-17 | ||||
| 2019-12-31 | -$2.36M 10-K · filed 2021-03-31 | ||||
| 2019-09-30 | -$1.53M derived: 10-Q 9 month − 8-K 6 month · filed 2020-11-16 | -$2.61M 10-Q · filed 2020-11-16 | |||
| 2019-06-30 | -$1.08M 8-K · filed 2020-09-29 | ||||
| 2019-01-31 | -$48.97M 10-K · filed 2021-03-31 | ||||
| 2018-01-31 | $13.76M 8-K · filed 2020-09-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |